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Abstract 
We report the development of a simple and powerful capacitive aptasensor for the 
detection and estimation of human epidermal growth factor receptor 2 (HER2), a biomarker for 
breast cancer, in undiluted serum. The study involves the incorporation of interdigitated gold 
electrodes, which were used to prepare the electrochemical platform. A thiol terminated DNA 
aptamer with affinity for HER2 was used to prepare the bio-recognition layer via self-assembly 
on interdigitated gold surfaces. Non-specific binding was prevented by blocking free spaces on 
surface via starting block phosphate buffer saline-tween20 blocker. The sensor was 
characterized using cyclic voltammetry, electrochemical impedance spectroscopy (EIS), atomic 
force microscopy and contact angle studies. Non-Faradic EIS measurements were utilized to 
investigate the sensor performance via monitoring of the changes in capacitance. The 
aptasensor exhibited logarithmically detection of HER2 from 1 pM to 100 nM in both buffer 
and undiluted serum with limits of detection lower than 1 pM. The results pave the way to 
develop other aptamer-based biosensors for protein biomarkers detection in undiluted serum. 
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1. Introduction 
Breast cancer is one of the most common cancers and the second major cause of deaths 
in women worldwide (Diaconu et al. 2013; Siegel et al. 2013). More than 90% of these deaths 
are related to metastatic growth (Siegel et al. 2013). Therefore, early stage detection of cancer 
is crucial to increase the chances of survival. Human epidermal growth factor receptors 
(HER/erbB) are involved in normal growth and cell differentiation, however a malignant 
growth can be related with overexpression of human epidermal growth factor receptor 2 
(HER2), a transmembrane tyrosine kinase receptor expressed and involved in the growth of 
certain cancer cells. It is present in some cases of breast, ovarian, lung, gastric, oral, prostate 
and other cancers (Patris et al. 2014). HER2 has also been shown to be overexpressed in around 
20–30% of aggressive breast cancers and associated with poor prognosis (Diaconu et al. 2013). 
Breast cancer patients possess high HER2 concentrations in their blood (14–75 ng/ml) 
compared to normal individuals (4–14 ng/ml) and can be utilized for diagnosis and active 
surveillance of patients at risk or in treatment (Chun et al. 2013; Hung et al. 1995). To evaluate 
these concentrations, various HER2 detection techniques have been reported, including 
fluorescence in situ hybridization (FISH) assays and immunohistochemical (IHC) assays (Press 
et al. 2002). However, these techniques require sophisticated instrumentation, special training, 
are labour-intensive and time-consuming. 
To satisfy the unmet clinical need of point-of-care biomarker detection, several 
biosensors that use enzymes, receptors and antibodies have been reported (Camacho et al. 2009; 
Wang et al. 2009b). One of the disadvantages of using antibodies is their instability due to 
irreversible denaturation. Therefore, alternative bio-recognition elements are desirable to 
develop stable biosensors. Synthetic molecules such as oligonucleotide aptamers have shown 
great promise to fulfil these gaps associated with biomarkers. Aptamers, single strand 
oligonucleotides (DNA or RNA) that are designed and developed synthetically in the 
laboratory, have been shown to bind to specific targets such as proteins (Qureshi et al. 2015). 
Aptamers are known to be more stable, cheaper, are easily modified chemically and can be 
easily produced in bulk. Furthermore, the unique binding properties of aptamers have shown 
great potential for biosensors using optical, electrochemical, and mass-sensitive approaches 
(Cho et al. 2009; Qureshi et al. 2015).  
Among various types of biosensors, electrochemical techniques have gained much 
interest due to their simplicity, miniaturizability, faster and more sensitive response (Arya and 
Bhansali 2012; Bollella et al. 2017; Wang et al. 2017). For electrochemical biosensor 
preparation, self-assembled monolayers (SAM), magnetic beads and nanomaterials such as 
graphene and nanocomposites have gained considerable attention (Arya et al. 2009; Filip et al. 
2015; Hammond et al. 2016; Kurlyandskaya and Miyar 2007; Lan et al. 2017; Selwyna et al. 
2013). Although nanomaterial-based sensors can be fabricated with high sensitivity due to e.g. 
high surface-to-volume ratios, the use of SAMs on microelectrodes has the advantage of simple 
single-step biomolecular surface chemistries with high reproducibility and low cost. Among 
electrochemical biosensors, electrochemical impedance spectroscopy (EIS)-based biosensors 
are recently gaining much attention (Barsoukov and Macdonald 2005; Gong et al. 2017; Guan 
et al. 2004; Katz and Willner 2003). EIS based biosensors allow the label-free detection of an 
analyte binding to a bio-recognition layer at the electrode surface and can be measured in the 
form of changes in capacitance and/or resistance (Ramón-Azcón et al. 2008). It has been shown 
in the literature that the use of interdigitated microelectrodes (IDµEs) to develop EIS-based 
biosensors present additional advantages of faster reaction kinetics, enhanced sensitivity and 
improved signal-to-noise ratio (Arya and Bhansali 2012; Ramón-Azcón et al. 2008; Wang et 
al. 2009a). Moreover, due to faster mass transport with a lower iR drop and double layer 
charging effects, IDµEs attain steady state faster, resulting in easier measurement than with 
conventional macroelectrodes (Arya and Bhansali 2012; Varshney and Li 2009). 
Impedimetric biosensors can be operated in both Faradaic and non-Faradaic modes. In 
Faradaic impedance, a redox couple is required, which is interchangeably oxidized and reduced 
via electron transfer to and from the electrode surface (Daniels and Pourmand 2007); 
transduction happens via changes in the hindrance presented by the surface interface to a redox-
containing solution phase (Arya et al. 2014; Santos et al. 2014). On the other hand, in a non-
Faradaic measurement charging currents are dominant and capacitive changes occurring via 
changes in the hindrance presented by the surface dielectric, charge distribution or local 
conductance are monitored (Berggren et al. 2001; Luo and Davis 2013). Non-Faradaic 
approaches have the advantage of not requiring the pre-addition of redox probes to the 
analytical solution and can be applied for highly sensitive detection of analytes in a more 
amenable manner for point-of-care applications (Berggren et al. 2001; Daniels and Pourmand 
2007; Qureshi et al. 2010). Furthermore, for practical applications, where the measurement in 
real samples is required, non-Faradaic measurements are desirable. Non-Faradaic 
electrochemical impedance spectroscopy (EIS) has also been used to characterize the interfacial 
properties of biomaterials or cells associated with conductive or semiconductive devices, where 
the measured signals are attributed to the insulating effects of biomaterials or membranes of 
cells that grow on or attach to the sensing surface (Lin et al. 2015). Such capacitance change 
may arise when a target protein binds to the receptor immobilized onto electrode surface, 
displacing water molecules and ions away from the surface (Tkac and Davis 2009), or due to 
varying protein conformation (Berggren et al. 2001). 
In this study, the combination of interdigitated micro electrodes (IDµE), DNA aptamers 
and capacitive measurements has been utilized to develop a simple and sensitive biosensor for 
HER2 protein biomarker estimation. HER2 can be estimated using direct measurement of the 
serum protein levels or by analysis of HER2 nucleic acid sequences. Direct protein 
measurement, as the one presented in this work, makes sample processing easier and hence 
amenable for use in a point-of-care platform. For biosensor development, gold IDµE chips were 
functionalized with DNA aptamers via self-assembly and used for specific capture of HER2 
protein. The surface was further blocked using phosphate buffer saline-tween 20 based starting 
block (SB) to prevent non-specific binding and fouling of the surface. The non-Faradaic 
electrochemical impedance spectroscopy was utilized to quantify HER2 binding events in 
buffer and serum samples by monitoring the changes in capacitance.  
 
2. Experimental 
2.1. Materials 
Thiol terminated HER2 specific DNA aptamer (5’-SH-(CH2)6-AAC CGC CCA AAT 
CCC TAA GAG TCT GCA CTT GTC ATT TTG TAT ATG TAT TTG GTT TTT GGC TCT 
CAC AGA CAC ACT ACA CAC GCA CA-3’) was procured from Sigma (UK). This HER2 
aptamer sequence was taken from the report of Liu et al. (2012), where the authors have 
developed and characterized the aptamer (HB5) by using systematic evolution of ligands by 
exponential enrichment technology (SELEX). The developed aptamer was an 86-nucleotide 
DNA molecule that bound to an epitope peptide of HER2 with a Kd of 18.9 nM. For binding 
studies, different concentrations of HER2 (R&D Systems, UK) and other targets were prepared 
in 10 mM PBS, pH 7.4 or in undiluted serum. StartingBlock phosphate buffer saline-Tween 20 
(SB) was procured from Fisher Scientific (UK); Dulbecco’s phosphate buffered saline (PBS) 
and phosphate buffered saline with 0.05% tween 20 (PBST-20) were procured from Sigma 
(UK). All other chemicals were of analytical grade and were used without further purification. 
All aqueous solutions were prepared using 18.2 MΩ cm ultra-pure water (milli-Q water) with 
a Pyrogard® filter (Millipore, MA, USA). 
 
2.2. Measurement and apparatus  
Blank and aptamer modified IDµE chips were characterized via atomic force 
microscopy (AFM) imaging in ambient tapping mode using a MultiMode NanoScope with IIIa 
controller (Bruker, Germany) in conjunction with version 6 control software. AFM images were 
recorded using 10 nm diameter AFM ContAl-G tips (BudgetSensors®, Bulgaria), and then 
processed by the NanoScope Analysis software, version 1.5. Aptamer binding was also 
characterized via contact angle measurements using an in-house built optical angle 
measurement system (Miodek et al. 2015). For measurement, chips were placed on a stage and 
a 10 µl of water drop was dispensed on the electrode with the dispensing system. The wetting 
of surface was then captured using a Nikon p520 camera. Contact angle was measured using a 
screen protractor version 4.0 procured from Iconico. 
Biosensor fabrication was also characterized electrochemically in Faradaic mode via 
electrochemical impedance spectroscopy (EIS) and cyclic voltammetry (CV) in a three-
electrode configuration with on-chip gold (2 mm wide) as counter and pseudo reference 
electrode. EIS measurements were performed at open circuit potential (equilibrium potential), 
without external biasing in the frequency range of 100 kHz – 100 mHz with a 25 mV amplitude 
using a µAutolab III / FRA2 potentiostat/galvanostat (Metrohm, Netherlands). EIS and CV 
measurements were carried out using 50 μl of PBS solution (10 mM, pH 7.4) containing a 
mixture of 5 mM Fe(CN)6
4− (ferrocyanide) and 5 mM of Fe(CN)6
3− (ferricyanide) as a redox 
probe couple. Non-Faradaic EIS measurements on IDµEs (in the absence of redox couple) using 
a two-electrode configuration were utilized for HER2 detection and estimation in 10 mM PBS 
(pH 7.4) in a frequency range 100 kHz – 100 mHz with a 200 mV amplitude. Each experiment 
has been done at least in triplicated using different sensors. Only the optimized sensors in terms 
of concentration of reagents providing reproducible, reliable and sensitive performance are 
presented here. 
 
2.3 Electrode preparation and functionalisation 
2.3.1 Gold electrode fabrication 
The deposition of interdigitated gold micro-electrode arrays on silicon/silicon oxide 
wafers was performed using standard lithographic and micro-fabrication techniques as 
previously described (Pui et al. 2013). The 3200 μm long interdigitated fingers of 5 μm, spaced 
at 10 μm and attached to single base of 5500 μm length were deposited and utilized for 
biosensor development. The prepared IDµEs were cleaned thoroughly with isopropyl alcohol, 
acetone and with excess amounts of milli-Q water followed by 30 min UV-ozone treatment 
(ProCleaner, BioForce Nanosciences, USA) before aptamer functionalization.   
 
2.3.2 Aptamer assembly and blocking 
For thiolated aptamer assembly and immobilization on IDµEs, stock aptamer 
immobilisation solution (100 µM in tris buffer) was heated to 95°C for 5 min followed by ice 
cooling to room temperature and thereafter, diluted to 2 µM solution in PBS 1x pH 7.4. Pre-
cleaned IDµEs were then incubated with 2 µM aptamer solution for 120 min at room 
temperature. Later, the chips were washed with PBST-20 (pH 7.4) and PBS (10 mM. pH 7.4) 
to remove any unbound aptamers. The free spaces on the chip were blocked using SB 
incubation for 30 min, after which extra solution was removed and the developed sensor 
electrodes were stored at 4oC till further use. Figure 1 shows the schematic for aptasensor 
electrode preparation. During the electrode preparation, the thiolated aptamer forms a self-
assembled monolayer (SAM) on the old surface of chip via interactions between the alkane 
chains on the 5’. The SB blocker fills the free spaces between aptamer molecules on the chip 
and prevents the non-specific adsorption of serum proteins on the surface during incubation. 
Furthermore, the two middle IDµEs provide the opportunity to use a two-electrode system for 
non-Faradaic measurement of HER2 without any redox couple. 
  
Figure 1. Schematic for aptasensor electrode preparation 
 
3. Results and Discussion 
3.1. Characterisation of the biosensor fabrication 
3.1.1 Contact angle and AFM measurements 
Figures 2a and 2b show the variation of contact angle of blank gold and after aptamer 
immobilization. The clear decrease in contact angle value from 23º for blank gold to 10º for the 
aptamer/IDµE suggests the successful formation of an aptamer self-assembled monolayer 
(SAM). Furthermore, Figures 2c and 2d show the AFM images of blank gold and aptamer 
modified surface taken in tapping mode using a 10 nm AFM tip. The observed change in non-
uniform morphology for blank gold (Figure 2c) surface to uniformly distributed structure 
(Figure 2d) for aptamer modified IDµE confirms the successful SAM formation by thiolated 
aptamer. The mean roughness (Ra) and maximum roughness (Rmax) change from 1.46 nm and 
11.8 nm for blank to 1.36 and 9.53 nm for the aptamer modified surface, respectively, indicating 
surface functionalization. These changes could be attributed to aptamer binding making the 
surface smoother.  
Aptamer
Blocking
Her2
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Figure 2. Contact angle image for (a) blank cleaned gold surface, (b) after aptamer SAM 
formation and AFM image for (c) blank cleaned gold surface, (d) after aptamer SAM formation  
 
3.2 CV and EIS characterization for biosensor development 
 In order to further confirm the aptamer immobilization, the sensor was characterized 
using cyclic voltammetry (CV) in PBS (1x) containing 5 mM potassium ferrocynide and 5 mM 
potassium ferricynide, [Fe(CN)6]
3-/4-. Figure 3a shows a decrease in peak current from 156 µA 
for blank IDµE to 132 µA for aptamer SAM, indicating successful SAM formation. 
Furthermore, the reduction in peak current to 96 µA after blocking confirms the filling of free 
surface on IDµEs with blocker proteins. Figure 3b shows the Nyquist plots for each step, with 
an increase in charge transfer resistance (Rct) from 217  for blank chip to 661  after aptamer 
SAM formation, again revealing successful immobilization. The increase in Rct to 1021  after 
(c) (d)
blocking can be attributed to adsorption of non-conducting blocker proteins in free areas of the 
gold electrodes. 
Blank, aptamer modified and after blocking electrodes were further investigated under 
different scan rates (30 – 100 mV/s), and oxidation and reduction peaks were observed even 
after aptamer SAM formation and blocking, suggesting good redox activity of the electrodes. 
Moreover, the observed linear variation in oxidation peak currents with square root of scan rate 
(Figures 3c) obeying equations 1 to 3, suggests a diffusion controlled process on sensor surface 
(Vasudev et al. 2013). For repeated sets, the error was found to be less than 2% for blank chips, 
increasing to around 4% for fabricated chips after aptamer binding and blocking with SB. 
Ioxi (Blank IDµE) (µA) = -21.62 µA + 796.85 (Scan rate)
1/2 µA; r2 = 0.999   (1) 
I oxi (Aptamer/IDµE) (µA) = 18.99 µA + 504.33 (Scan rate)
1/2 µA; r2 = 0.999   (2) 
I oxi (SB-Aptamer/IDµE) (µA) = 20.69 µA + 340.81 (Scan rate)
1/2 µA; r2 = 0.991   (3) 
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 Figure 3. Characterization of biosensor electrode fabrication at each step via (a) CV, (b) EIS 
and (c) scan rates study showing oxidation peak current response as a function of square root 
of scan rate. 
 
3.2 HER2 studies  
3.2.1 Capacitive measurement via electrochemical impedance for HER2 in PBS 
The SB-Aptamer/IDµE bio-electrodes were utilized to study aptamer-HER2 binding on 
surface in the 1 pM to 100 nM concentration range (Figure 4). For the measurements, 50 µl of 
the desired HER2 concentrations were placed in contact with the bio-electrode and incubated 
for 30 min, followed by washing with PBST20 and PBS to remove unbound HER2 molecules. 
The non-Faradic EIS spectra was then recorded in 10 mM PBS (pH 7.4) and then 1/ωZ'' (ω is 
the angular frequency and Z'' the imaginary part of the impedance) was utilized to estimate the 
capacitance of the system. A maximum in the phase angle (Figure 4a) was observed at 2 Hz, 
indicating maximum a capacitive effect at this frequency. Capacitive values at 2 Hz (Figure 4b) 
were then utilized to plot the calibration curve for HER2 concentrations in PBS (Figure 4c). 
The decreasing capacitance values observed for increasing HER2 concentrations is attributed 
to the successful capture of HER2 proteins onto the surface bound aptamer. This change in 
capacitance in non-Faradaic measurement can be attributed to the insulating effects of HER2 
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proteins that attach to the sensing surface and displacing water molecules/ions away from the 
surface (Tkac and Davis 2009), or due to varying aptamer/protein conformation (Berggren et 
al. 2001). The calibration plot generated using relative change in capacitance (Figure 4c) shows 
that the bio-electrode can be used for linear detection of HER2 on logarithmic scale in the 1 
pM to 100 nM range and can be characterized using ΔC (µF) = 0.049 (µF) + 0.071 log [HER2] 
(pM). Furthermore, the bio-electrode exhibited a sensitivity of 0.071 µF/ log([HER2] pM) and 
a correlation coefficient of 0.982. Different electrodes were found to exhibit similar responses 
within 5% as shown by the error bars in Figure 4c.  
     
 
Figure 4. (a) Phase data, (b) capacitance data for aptamer-HER2 binding on biosensor surface 
in PBS and (c) calibration curve using capacitance data for different concentration at 2 Hz 
 
3.2.2 Capacitive measurement via electrochemical impedance for HER2 in undiluted serum 
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In order to test the applicability of the sensors for clinical applications, SB-
Aptamer/IDµE bio-electrodes were tested with undiluted serum spiked with HER2. This 
enabled to study the effect of all types of serum proteins on the interaction between surface 
bound aptamer and HER2 molecules in the concentration range 1 pM to 100 nM (Figure 5). 
Similarly to HER2 in PBS, the bioassay and non-Faradaic EIS measurements were carried out 
for HER2 in serum and the capacitance calculated for different HER2 concentrations (Figure 
5b). Capacitance values at 1 Hz, where the maximum phase angle is observed (Figure 5a), were 
used for the calibration curve in Figure 5c. The observed maximum in phase angle at slightly 
lower frequency may be attributed to the presence of serum proteins and different conductivity 
and ionic strength of HER2 in the serum samples as compared to the HER2 samples in PBS. 
The plots in Figure 5b, showing a decrease in capacitance for increasing HER2 concentrations 
in serum, clearly indicate that the bio-electrode can be successfully utilized for HER2 
estimation in serum. The calibration plot in Figure 5c indicates that the bio-electrodes can be 
used for detection of HER2 in the range 1 pM to 100 nM at 1 Hz and can be characterized using 
ΔC (µF) = 0.057 (µF) + 0.035 log [HER2] (pM). Furthermore, the bio-electrode exhibited a 
sensitivity of 0.035 µF/ log([HER2] pM) with a correlation coefficient of 0.98. Different 
electrodes were found to exhibit similar responses within 5%, as shown by the error bars in 
Figure 5c. The observed lower sensitivity of 0.035 µF/ log([HER2] pM) for HER2 detection in 
serum in comparison to 0.071 µF/ log([HER2] pM) in PBS might be attributed to the presence 
of serum proteins in the sample causing hindrance in aptamer-HER2 interaction. Repeated 
experiments showed similar and consistent responses, indicating that the lower sensitivity in 
serum samples will not affect the accurate estimation of HER2. Furthermore, other than serum 
proteins, the bio-electrodes were also tested for specificity against proteins such as PSA (at a 
high concentration of 100 ng/ml), thrombin (100 ng/ml) and HER4 (100 ng/ml) spiked in serum 
(data not shown) and found to exhibit negligible signal when compared with signal for the 
serum only samples, indicating good selectivity of the developed electrode. Furthermore, other 
than serum proteins, the bio-electrodes were also tested for specificity against proteins such as 
PSA (at a high concentration of 100 ng/ml), thrombin (100 ng/ml) and HER4 (100 ng/ml) 
spiked in serum (Figure 5d). From Fig 5d, it is clear that bio-electrode is specific and exhibits 
negligible signals for interferents when compared with the signal for the serum only samples. 
The data obtained in this work was compared to other sensors reported in the literature 
for HER2 estimation (Table 1). The present system exhibits better response than those 
previously reported and can be utilized for real sample applications. It should be noted that 
Qureshi et al. (2015) obtained a similar LOD with interdigitated electrodes but their work was 
carried out at high frequencies (50–350 MHz), which are difficult to implement in a low cost 
point-of-care system; also the dynamic range in that work is considerably smaller (0.2–2 ng/ml), 
requires longer incubation times (2h) and 10 times dilution of serum.  
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 Figure 5. (a) Phase data, (b) capacitance data for interaction between surface bound aptamer 
with HER2 concentrations in undiluted serum, (c) calibration curve using capacitance data for 
different concentration at 1 Hz, (d) capacitance data for interference study. 
 
Table 1: Comparison between the present approach and state-of-art technologies 
Technique Electrode/Surface Probe LOD Reference 
Fluorescence Carbon nanotube wrapped 
anti-HER2 ssDNA 
aptamers 
Aptamer 4750 ng/ml 
(38 nM) 
(Niazi et 
al. 2015) 
Microfluidic with 
fluorescence 
transduction 
Quantum Dots (QD) Immunoassay / Antibody 0.27 ng/ml (Jokerst et 
al. 2009) 
Opto-fluidic ring 
resonator (OFRR) 
Silica glass capillaries 
modified with cross-
linkers to bind protein G 
Antibody 10 ng/ml (Gohring 
et al. 2010) 
Surface plasmon 
resonance (SPR) 
spectroscopy 
Protein G based Antibody 11 ng/ml (Martin et 
al. 2006) 
Surface acoustic 
wave (SAW) 
SAW resonator with gold 
transducer 
Antibody 10 ng/ml (Gruhl et 
al. 2010) 
Surface acoustic 
wave (SAW) 
SAW resonators based on 
36o YX-Li-TaO3 
substrates 
Antibody 10 ng/ml (Gruhl and 
Länge 
2012) 
Amperometric 
(CV)  
Carbon screen printed 
electrodes  
Nano-Immunoassay / 
Antibody 
1000 ng/ml (Patris et 
al. 2014) 
EIS Gold nanostructured 
screen-printed graphite 
Affibody 6 ng/ml (Ravalli et 
al. 2015)  
Capacitance Interdigitated 
microelectrodes 
Aptamer 0.2 ng/ml (Qureshi et 
al. 2015) 
Capacitance  Interdigitated electrodes Aptamer 0.1 ng/ml (1 
pM) 
Present 
study 
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 4. Conclusion 
An aptamer based capacitive biosensor strategy has been demonstrated for the detection 
of HER2 in undiluted serum. The biosensor showed excellent selectivity when challenged with 
other serum proteins. The prepared biosensor exhibited a wide HER2 detection dynamic range 
from 1 pM to 100 nM range, with a high sensitivity of 0.035 µF/ log([HER2] pM) in undiluted 
serum. The detection limits are lower than those previously reported in the literature for HER2 
sensing, enabling better early cancer diagnosis and monitoring of cancer progression and/or 
treatment. Measurements can be performed at a single frequency, making instrumentation for 
a point-of-care device easy to implement. Furthermore, the fabrication method is simple and 
can be applied for the detection of other biomarkers in serum samples, paving the way to a new 
generation of alternative low cost and rapid biosensors. 
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